WE CARE ABOUT RARE DISEASE PATIENTS

FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)

Sobi’s product portfolio is primarily focused on inflammation and genetic diseases.

Data presented at ASH support emapalumab as an innovative, targeted therapeutic option for primary HLH